Clinical & Translational Radiation Oncology

Open access journal by ESTRO

[Clinical & Translational Radiation Oncology @ctRO_journal]

👉 94 patients with isolated local relapse of prostate cancer after definitive irradiation.
👉 Salvage I-125 low-dose-rate brachytherapy was performed in a Comprehensive Cancer Center.
👉 Treatment of whole gland (70%) +- with an MRI-based GTV boost (20%) or focal (10%).

[Clinical & Translational Radiation Oncology @ctRO_journal]

https://t.co/JIDfKSINzb

[Clinical & Translational Radiation Oncology @ctRO_journal]

https://t.co/Sjzms56sLk

[Clinical & Translational Radiation Oncology @ctRO_journal]

https://t.co/2AXGds0Lsh

[Clinical & Translational Radiation Oncology @ctRO_journal]

https://t.co/iEiVPd77m2

[Clinical & Translational Radiation Oncology @ctRO_journal]

https://t.co/ZtKN8L8yE1

[Matthias Guckenberger @Mat_Guc]

Compliance to MDT recs in OMD pts:
👉83.7% of MDT recommendations correctly implemented
👉Reasons for major deviations: physician decision, patient comorbidity or patient decision.
👉Major deviations associated with more than one distant met and worse OS
https://t.co/z2D6i8hYWl

[Cihan Gani @GI_RadOnc]

A day in the life of an editor in chief... @ctro_journal #radonc

[Clinical & Translational Radiation Oncology @ctRO_journal]

👉Nomogram developed by authors predicting outcomes. #radonc

[Clinical & Translational Radiation Oncology @ctRO_journal]

🎆 Now in @ctRO_journal
Impact of Dose, fractionation and motion management on SBRT outcome in adrenal gland tumors. #radonc

[Clinical & Translational Radiation Oncology @ctRO_journal]

Also don't miss the accompanying editorial by @cristian_udo @SahgalArjun @HaghighiNeda @drhsoli
https://t.co/LYh5uL8Kvv #radonc

[Clinical & Translational Radiation Oncology @ctRO_journal]

Hot off the press in ctRO by Rogers et al.

🔷 Preoperative Radiosurgery is highly feasible when scheduled the day before neurosurgery.
🔷 The surgical cavity local control rate was equivalent to that reported with postoperative fractionated SRS

https://t.co/2Jgyf9G5Rw
#radonc

[Cristian Udovicich @cristian_udo]

Should preoperative SRS be considered for brain metastases undergoing resection? Great to work with @HaghighiNeda @SahgalArjun @drhsoli on our @ctRO_journal editorial of the PREOP-1 trial. More prospective evidence for this novel paradigm! @Sunnybrook @UofTDRO @PeterMacRadOnc @PeterMacCC @ESTRO_RT @RadiotherapyOn1 #btsm

[Clinical & Translational Radiation Oncology @ctRO_journal]

🔹LDR Brachytherapy for recurrent prostate cancer after definitive radiotherapy

https://t.co/476srxhZJI

#radonc

[Clinical & Translational Radiation Oncology @ctRO_journal]

🦴 Study on Osteolytic Metastases (SM) Remineralization
🔬 Conclusion: Radiation therapy significantly increases BMD in lytic SM (except renal tumors). No additional benefit of SBRT over cEBRT. Important for surgical decisions in unstable patients.
https://t.co/SNv7Yt1uXg

[Clinical & Translational Radiation Oncology @ctRO_journal]

We are hiring!! We are looking for two associate editors for @ctro_journal! Apply now if you want to be part of a rapidly growing radiotherapy journal by @ESTRO_RT!
https://t.co/eSRRQvNRc8
#radonc

[Krishan Jethwa @KrishanJethwa]

And now... updated results of 41 patients CURATIVELY treated with 6m of Dostarlimab (PD-1) WITHOUT ☢️or🔪

✅100% cCR rate
✅0 Local or distance relapses
✅Sustained cCR for > 12 m seen in 20 patients with mFU of 29 m

THIS. IS. AWESOME

#ASCO24

[Noemi Reguart @NReguart]

LAURA Trial receives a well deserved huge applause by the audience. Huge benefit in PFS (39 vs 5.6 mo, HR < 0.2. OS still immature and 81% crossover. STAGE III EGFR+ NSCLC INCURABLE? BRAIN RMN BUT NO PET-CT required at baseline. #ASCO24 @LeciaSequist

[Clinical & Translational Radiation Oncology @ctRO_journal]

Your turn now to submit 👍
https://t.co/zZ8HZOiUBb

[Clinical & Translational Radiation Oncology @ctRO_journal]

🌟 Check out these examples showcasing the scope of @ctro_journal! 📝🔬 #radonc

[Clinical & Translational Radiation Oncology @ctRO_journal]

...another fascinating study... https://t.co/7vGJmqUnzu